Drilldown: Medicines
Appearance
Medicines > classes
:
Analgesic
or
Cathinone
or
[[:Category:Tricyclic antidepressants|Tricyclic antidepressant (TCA 
:
Analgesic
or
Cathinone
or
[[:Category:Tricyclic antidepressants|Tricyclic antidepressant (TCA 
Use the filters below to narrow your results.
3-MMC (1) ·
Buprenorphine (1) ·
Butorphanol (1) ·
Butylone (1) ·
Cathinone (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylmorphine (1) ·
Ethylone (1) ·
Fentanyl (1) ·
Hexedrone (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Mephedrone (1) ·
Methadone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Nalbuphine (1) ·
Nortriptyline (hydrochloride) (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Pentedrone (1) ·
Tapentadol (1)
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
'"`UNIQ--vote-00000019-QINU`"' Therapeutic plasma-level monitoring is standard practice for TCAs given the narrow therapeutic index and the established plasma-level-efficacy correlation. CYP2D6 substrate; CPIC PGx guidance applies for dose individualization'"`UNIQ--ref-0000001A-QINU`"'. (1)
None (31) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
TCA class signal; limited human data specific to nortriptyline.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 33 results in range #1 to #33.

